本帖最后由 老马 于 2012-1-13 21:20 编辑 ! ]! y9 I& j% x6 T0 H- Z
) P- P: Z- u3 z5 R. B: F1 z爱必妥和阿瓦斯丁的比较0 U# \# E6 O0 l
' C7 o2 k: e8 f8 o& k
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
# v' y0 u" g' F. J- Q! U
2 ~+ ~, a N2 M$ m8 _0 L) a
* v8 C3 S1 l( L/ Z) Ihttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/' u4 _1 S/ u) @4 q M
==================================================
0 K6 J7 \7 B' C+ mOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
& d' i) P: }' V9 ?* j2 C" DPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
7 n9 X/ Q4 b$ ^, s# CResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; [- e. u, u c( b9 y6 {
|